GLP-1 Agonist Impact How Medications Reduce Snacking Habits
Full article

Abstract Background Several Glucagon-like peptide-1 ( GLP-1 ) receptor agonists are FDA-approved for weight loss in patients with obesity primarily through targeting gastrointestinal pathways to reduce caloric intake; however, less is known about the GLP-1 receptor agonist impact on the behavioral aspects of eating.

In many ways, the impact of GLP-1s is reinforcing trends already in motion. Food manufacturers and retailers are reassessing traditional product lines, focusing on offerings that emphasize premium, indulgent snacking - think functional beverages, high-protein and high-fiber foods, and supplements that address GLP-1 side effects.
How are Ozempic and other GLP

How is the rising popularity of GLP-1 drugs impacting snacking ? The increase in GLP-1 drug use has changed eating habits, particularly regarding snacking (see figure). Users tend to eat less overall, and this includes less snacking .
Abstract Widespread adoption of Glucagon-like peptide-1 ( GLP-1 ) agonists could cause significant changes in food consumption and preferences that disrupt the food industry. In this study, we survey four consumer groups to better understand how GLP-1 s may affect food consumption and preferences. The four groups were: 1 ) consumers currently using a GLP-1 , 2) consumers who have previously used a ...

Changes in food preferences and ingestive behaviors after ...
The main outcomes analyzed from each study are the impact of GLP-1 analogs on ingestive behavior, cravings and craving control, and differential effects in the weight loss and weight maintenance ...
Growing usage of GLP-1 drugs for weight loss may significantly slow growth in traditional food categories, especially snack foods. Read more.

Diet quality and nutrient distribution while using glucagon
With the rise of glucagon-like-peptide-1 receptor agonist medications ( GLP -1RA) for obesity treatment, understanding diet quality can be a valuable tool for providing evidence-based nutrition guidance. However, there is limited data on dietary intake during GLP -1RA treatment. Thus, we analyzed diet quality and nutrient timing while using GLP -1RA.
This JAMA Internal Medicine Patient Page describes how glucagon-like peptide-1 ( GLP-1 ) receptor agonists work and what behaviors to adopt while using them.

The No
The authors examine how consumers modify their food purchases after adopting appetite-suppressing GLP-1 receptor agonists , such as Ozempic and Wegovy. Using survey responses on medication adoption linked to transaction data from a representative U.S. household panel, the authors document the prevalence, motivations, and demographic patterns of GLP-1 adoption. Households with at least one GLP-1 ...











































GLP-1 medications like Ozempic and Wegovy aren't just reshaping waistlines. They're disrupting the business of appetite itself. And in doing so, they pose a new existential question for the bakery and snacks sectors: what happens to those categories built on indulgence when hunger disappears?